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Lymphocytes of the immune system become activated in order to fight pathogens. Activated 
lymphocytes absorb more glucose due to their high-energy demand.  Glycogen is a branched polymer 
of glucose units that is formed in times of nutrient sufficiency and it is utilized in times of need. In the 
presence of high glucose, lymphocytes build up glycogen stores, but the fate of this content is not 
very well understood. The objective of this work is to demonstrate the presence of glycogen in 
activated human peripheral blood mononuclear cells (PBMCs) and to investigate the impact of low 
nutrient levels on the glycogen content of these cells. This was achieved by isolation of PBMCs from 
human blood, followed by in-vitro activation of the cells by a general activator and a T cell-specific 
activator. Glycogen concentrations were measured through periodic acid Schiff’s staining (PAS) 
method and by using an enzymatic detection kit, in various time points. The role of glycogen in times 
of low nutrient availability was also examined. PBMC were found to contain glycogen by both 
methods. Upon stimulation of PBMCs with the general activator, there was an increase in glycogen 
formation in the activated lymphocytes as compared to the non-activated group using both 
techniques (p<0.05). The effect of T cell-specific activator was consistent with the effects of the 
general activator. This was confirmed through PAS staining and enzymatic detection kit techniques 
(p<0.05). Additionally, when the amount of nutrients was lowered, less glycogen was stored in 
PBMCs. This study demonstrated that activated PBMCs contain more glycogen stores as compared to 
non-activated cells. The excess glucose that is converted into glycogen may be used by the immune 
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Human Immune Cells 
Peripheral Blood Mononuclear Cells (PBMCs) are a subpopulation of immune cells 
composed of four main cell types; T Lymphocytes (T cells), B Lymphocytes, Natural Killer Cells 
and Monocytes. On average 70% of PBMCs are composed of T cells (Charles A Janeway, Travers, 
Walport, & Shlomchik, 2001). These cells originate from blood T cell precursors that are created 
in the bone marrow and migrate to thymus to mature. Once T cells enter the blood stream, 
they begin to circulate throughout the blood and lymphatic systems. In order to produce an 
adaptive immune response, T cells need to become activated, after which they proliferate (cell 
division), differentiate (change their properties), and coordinate other cells to eliminate the 
infection (Charles A Janeway et al., 2001; J. A. Maciolek, Pasternak, & Wilson, 2014; Pearce, 
2010).  
T Cell Activation 
Activation of T cells is caused by two main signals sent through the T cell receptor (TCR) and 
the CD28 co-stimulatory receptor. These signals are initiated by specialized immune cells called 
antigen-presenting cells (APC), which are constantly inspecting the body for pathogens. When 
an APC encounters a foreign antigen (for example from a pathogen), it uptakes the antigen 
through endocytosis and performs antigen processing. Ultimately, the APC creates a fragment 
of that antigen, termed the epitope. This epitope is then presented to T cells through the 
antigen binding groove of major histocompatibility complex (MHC) of the APC (Charles A 
Janeway et al., 2001; Roche & Furuta, 2015).  
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The TCR scans the presented antigen and if it recognizes the epitope, it induces several cell 
signalling pathways in the T cell via cluster of differentiation 3 (CD3) which is attached to the 
TCR (Charles A Janeway et al., 2001). The engagement of TCR with the antigen-MHC complex is 
the first signal required for activation of T cells. However, this signal is not sufficient for proper 
activation of T cells. There is a second required signal that is mediated by a cell surface receptor 
called CD28. This co-stimulatory signal will ensure cell survival and differentiation ability of 
activated T cells. CD28 of T cells will engage with CD80 and CD86 on APCs to create the co-
stimulatory signal and allow for full activation of T cells (Peach et al., 1995). One role of CD28 is 
to promote uptake of glucose, which is important because T Cells need sugar molecules, such as 
glucose, to survive (Candace M Cham et al. 2008; C. M. Cham and Gajewski 2005; Tripmacher et 
al. 2008; Chang et al. 2013). 
Upon activation of CD3 component of TCR, many pathways such as MAPK, P38 and JNK 
become activated. These pathways will ultimately stimulate the transcription factors required 
for activation of T cells. CD28 co-stimulation will also initiate many signalling transductions, 
including AKT/PI3K pathway, and PKC, which activates further growth signals. One of the 
outcomes of this pathway is the increase in the expression of glucose channels, which will 





Fig. 1) Activation Pathways and Glycogen Cycle  
 
Figure. 1) A) Upon the addition of anti-CD3 and anti-CD28, many signalling pathways are initiated which 
ultimately activate transcription factors necessary for activation. PMA interacts with PKC, which is 
involved in the pathways that are triggered upon activation of T cells. Glu-6-P = Glucose-6-
phosphorylase B) There are a number of enzymes involved in the breakdown and formation of 
glycogen. Upon activation of glycogen phosphorylase, the enzyme of the first and rate-limiting 
step of glycogen breakdown pathway, glucose units are released from glycogen. If blood 
glucose levels are high, the process reverses, and glycogen starts to build up again in the liver. 
Glycogen synthase, with the help of glycogenin, is responsible for adding glucose units to 




Activated immune cells secrete cytokines, which are cell-signalling proteins that stimulate 
cell growth, differentiation, survival, inflammation, and tissue repair (Fiore, Chaldakov, & Aloe, 
2009; Galazios, Papazoglou, Tsikouras, & Kolios, 2009; Mailloux et al., 2013). Interleukins (ILs) 
are a subset of cytokines that were first discovered to be secreted by immune cells (Brocker, 
Thompson, Matsumoto, Nebert, & Vasiliou, 2010). The presence of cytokines and interleukins 
in the media of PBMC cultures provides information on the efficiency of activation treatment.  
Some types of ILs are specific to certain cell types. Helper T cells (Th cells) have several distinct 
subtypes, denoted as Th1, Th2, and Th17 cells. Each one of these subtypes secretes a different 
combination of ILs. For example, Th1 cells secrete  IL-2 and IFN-γ ,  Th2 cells secrete IL-4, IL-5, IL-
10 and IL-13, and Th17 cells secrete IL-17 (Saraiva et al., 2009; Toscano et al., 2007; Zhu & Paul, 
2008). In PBMC cultures, IL-1β and IL-6 are likely to be secreted from monocytes, as compared 
to IL-17 which is specific to a subtype of T cells, and IL-2 which is secreted by all activated T cells 
(Brocker et al., 2010; Estruch et al., 2015). Another sign of activation is yellowing of the media, 
which is due to secretion of lactic acid as a byproduct of glycolysis, which makes the media 
more acidic and turns the phenol red from pink to yellow due to lactic acid excretion. 
Monitoring the pH of the culture and cytokine secretions are two methods of cell activation 
measurements. T cells can be activated in the laboratory with a general activator phorbol 
myristate acetate (PMA, which also activates other lymphocytes), or a specific activator that 




T cell Metabolism and Reprogramming upon Activation 
Activated T cells have a high-energy demand due to processes such as proliferation, 
differentiation and the secretion of cytokines. Activated T cells require an increased source of 
carbon, such as glucose, for the synthesis of macromolecules essential for an efficient immune 
response (Wang & Green, 2012). In order for T cells to meet this energy and carbon demand, 
the cells will go through modifications for better efficiency. This reprogramming includes 
increased glucose uptake due to the increase in the expression of Glucose Transporter 1 (Glut1), 
which is a glucose channel, and increased level of insulin receptors on the activated cells 
surface, which promote insulin dependent glucose-uptake (Ader, Poulin, Yang, & Bergman, 
1992; J. a. Maciolek, Alex Pasternak, & Wilson, 2014). One of the hallmarks of T cell activation is 
the switch from oxidative phosphorylation to anaerobic glycolysis in the presence of oxygen, 
known as the Warburg effect. This switch is  required for cytokine production (Chang et al., 
2013). Anaerobic glycolysis yields less ATP (Adenosine Triphosphate) and much more lactate as 
compared to oxidative phosphorylation. In order to compensate for this rapid use of glucose, 
activated T cells have an increased glucose uptake mediated through CD28 co-stimulatory 
signal (Frauwirth et al., 2002).  
What is Glycogen? 
Glycogen is a branched polymer of glucose, nucleated by the glycogenin protein (Berg, 
Tymoczko, & Stryer, 2002; Roach, Depaoli‑ Roach, Hurley, & Tagliabracci, 2012). The glucose-
glycogen cycle has been extensively studied in the context of the liver. When blood glucose 
levels are low, glycogen breakdown is promoted in the liver, which releases glucose into blood. 
Protein Kinase A (PKA) phosphorylates and thus activates phosphorylase kinase (PhK). Upon 
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activation of PhK, glycogen phosphorylase enzyme is activated causing the release of glucose 
units from glycogen in the form of Glucose 1-phosphate. Glycogen phosphorylase can only 
break down glucose units up to 4 residues away from a branching point. At this point in the 
cycle, the debranching enzymes transfer 3 of the remaining residues to another chain and 
release the glucose unit at the branch. The released glucose units have to be in the form of 
glucose 6-phosphate so it can be used in metabolism (Fig. 1B) (Berg et al., 2002; Greenberg, 
Jurczak, Danos, & Brady, 2006; Johnson, 1992; Meléndez, Meléndez-Hevia, & Canela, 1999; 
Roach et al., 2012; Tavridou & Agius, 2003). Glycogen breakdown in the liver will lead to the 
increase in glucose concentrations in the blood. When intracellular glucose  is too high, glucose-
6-phosphate can be converted back to glucose 1-phosphate by phosphoglucomutase enzyme. 
This form of glucose can then convert into UDP-glucose (Uridine diphosphate glucose) and 
enter the cycle to produce glycogen. Glycogenin is an enzyme that self glycosylates and creates 
glycogen primer of 3-4 glucose residues long. Glycogen synthase starts adding residues to the 
primer and creates a long chain of glucose units. The branching enzyme is responsible to 
change some of the α-1,4-glycosidic linkages to α-1,6-glycosidic bonds to create branches in the 
glycogen molecule (Fig. 1B). (Berg et al., 2002, Chapter 21; Ceulemans & Bollen, 2004; Cid, 
Geremia, Guinovart, & Ferrer, 2002; Forde & Dale, 2007; Ragolia & Begum, 1998; Roach et al., 





Glycogen in Immune Cells 
Glycogen metabolism is regulated by hormones such as glucagon and insulin in tissues such 
as muscle and liver (Roach et al., 2012; Villar-Palasi, 1968). There is evidence of the presence of 
glycogen in lymphocytes of the immune system as well. The existence of glycogen vacuoles in 
immune cells has been noted since 1950s, where researchers attempted to diagnose patients 
with various diseases based on the amount of glycogen that was accumulated in their 
lymphocytes (Drazancić & Janković, 1970; Hagemans et al., 2010; Jones, Goffi, & Hutt, 1962; 
Lilleyman et al., 1994; Sharvill, 1952). The use of glycogen content of immune cells as a 
diagnostic tool was inconclusive due to controversial findings (Jones, Goffi, and Hutt 1962; 
Leder and Donhuijsen 1978).  
The biological relevance of glycogen in lymphocytes remains a mystery.  The objective of 
this work was to fill this gap in the literature by demonstrating the presence of glycogen in 
human PBMCs, and investigating the impact of activation on the glycogen concentrations of 
these cells. The role of glycogen in times of low nutrient availability was also examined. It was 
hypothesized that upon activation of PBMCs, there will be an increase in glycogen expression 
and this storage can be used as a fuel source in times of nutrient insufficiency. The knowledge 
that was created in this project helps in better understanding of T cell fuel sources and the 
modifications these cells go through upon activation. This study is relevant in the field of T cell 
acute lymphatic leukemia (T-ALL) where glycogen content of lymphocytes is reduced in patients 
suffering from this disease (Andreewa, Huhn, Thiel, & Rodt, 1978; Huhn, 1984; Lilleyman et al., 
1994). This suggests that the glycogen pathway is altered in this form of cancer (See 
Supplementary Table 1). 
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Hypothesis 
PBMCs have glycogen stores that accumulate upon activation, and this content is 
proportional (responds) to changes in nutrient levels. 
Aims 
Aim 1: To demonstrate the presence of glycogen in PBMCs through two techniques of 
periodic acid Schiff (PAS) staining and enzymatic detection kit (glycogen assay).  
Aim 2: To investigate the effect of two different activators (general and T cell-specific 
activation) on the glycogen content of PBMCs.  
Aim 3: To address the influence of nutrient availability on the glycogen content of activated 
PBMCs. 
Materials and Methods 
Blood Draw and PBMC Purification 
Concordia University Ethics Review Board, certificate number 10000618, approved research 
with human blood samples. Healthy human subjects participated in this study. Heath status was 
determined by self-reporting. A nurse drew venous blood from the subjects by venipuncture, 
into heparinized (anti-coagulant) blood collection tubes. All steps of PBMC purification were 
done in a biosafety cabinet using sterile technique and the equipment had been sterilized by 
the manufacturer, or sterilized by using the autoclave machine. The blood was diluted at a 1:1 
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ratio with phosphate buffer saline (PBS 1X) in a conical tube and then layered on top of Ficoll, a 
nonionic synthetic polymer of sucrose. The tube was centrifuged at room temperature for 30 
minutes at 1800RPM (700 Xg) in a swinging bucket rotor with medium acceleration set to 5, and 
deceleration set to 0. 
The buffy coat was carefully collected using a transfer pipette. The buffy coat was identified 
visually as a thin cloudy white layer, where PBMCs are known to be located. PBS was added to 
the buffy coat to achieve a final volume of 45ml. After mixing, the buffy coat was centrifuged at 
room temperature for 15 minutes at 1500RPM (480 X g) with both maximum acceleration and 
deceleration set to 9. This was done to create a pellet of PBMCs at the bottom of the conical 
tube. The supernatant was discarded and the pellet was loosened by gently racking the tube 
against an undulated surface. Fresh PBS was added to the PBMCs and the tube was centrifuged 
at room temperature for 12 minutes at 1500RPM (480 X g) with both maximum acceleration 
and deceleration set to 9. The supernatant was discarded and fresh PBS was added. At this step 
the number of viable PBMCs was estimated based on the trypan counting (see details below). 
The desired amount of cells was taken and centrifuged at room temperature for 12 minutes at 
1200RPM (410 X g) with both maximum acceleration and deceleration set to 9. The supernatant 
was discarded and the PBMCs were re-suspended in the desired media. 
Trypan Blue Counting  
To check the number of viable cells, the trypan method was used. From the second to last 
step of the PBMC purification, 50µL of PBMCs in PBS was put in a microcentrifuge tube, to 
which an equal amount (50µL) of trypan blue, a vital stain, was added and mixed.  This stain is 
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only taken up by dead cells, which will appear blue in the count, live cells will appear clear. 10µL 
was taken out and transferred to a haemocytometer. The number of live cells was calculated 
with the following formula taken from manufacturer instructions (VWR).  
(




) 𝑋 106 = # 𝑜𝑓 𝑙𝑖𝑣𝑒 𝑐𝑒𝑙𝑙𝑠/𝑚𝐿 
 
Cell Culture Conditions 
Purified PBMCs were suspended in complete media. The media contained Roswell Parks 
Memorial Institute (RPMI), 5% fetal bovine serum (FBS), 1% penicillin (10,000 units/mLs), 1% L-
glutamine (200mM). After the treatments were added to the cells, the culture plate was kept in 
the incubator at 37oC and 5% CO2.  
PMA Activation of PBMCs 
Phorbol myristate acetate (PMA) was chosen as a general activator. PBMCs received PMA 
treatment (SIGMA) at a final concentration of 2ng/mL diluted in media. Each time point had a 
negative control group that did not receive PMA treatment.  
Anti-CD3, Anti-CD28 (T Cell-Specific) Activation of PBMCs 
PBMCs were incubated with anti-CD3 and anti-CD28 antibodies (eBioscience) at a final 
concentration of 0.1µg/ml each. Each time point had a negative control group that did not 
receive the activation treatment.  
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Serum Titration Experiment 
PBMCs were suspended in 2 mLs of complete media with T cell-specific activation mix at a 
final concentration of 0.1 µg/mL, in 6 wells of 24 well culture plate. Complete media was RPMI, 
5% fetal bovine serum (FBS), 1% penicillin, 1% L-glutamine. After 24 hours of incubation, the 
cells from the first well were lysed for glycogen analysis. This was the control group. The rest of 
the 5 wells were labeled group 1 to 5. After 24 hours of incubation, PBMCs settle down to the 
bottom of the plate. Half of the complete media (1mL) was carefully removed from the top of 
each well and was replaced with 1mL of a new media with fresh activation mix. Each group had 
a different new media added; group 1 new media was serum free, group 2 new media had 1% 
FBS, group 3 the media had 5% FBS, group 4 the media had 10% FBS and for group 5 the new 
media was at 12% FBS. The plate was incubated for another 24 hours. After the incubation 
period was over, once again 1mL of the media was taken out from the top of each well and was 
replaced with 1mL of new media appropriate for each group with activation mix. At this point 
final concentration of FBS in the wells was 1%, 2% 5%, 8% and 11%. After incubating the plate 
for 24 hours one last time, the cells from each well are taken out and lysed for glycogen analysis.  
Slide Preparation and Negative Control 
The PBMCs of interest were centrifuged and re-suspended in PBS. PBMCs in PBS were 
placed onto a labeled microscope slide. A smear was made with the help of another slide. The 
slide was left in a biological safety cabinet to air dry.  
Fixing the Slides 
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The fixative solution was prepared by mixing 0.5mLs of formaldehyde to 4.5mLs of ethanol. 
The final concentration of the fixative solution was 89.1% ethanol and 10.9% formaldehyde. 
When the slides were air dried, they were fixed with the freshly made fixative solution by 
immersing the slide in the solution for 1 minute and after, rinsing the slide for 1 minute.  
Amylase Treatment 
Amylase powder was dissolved in distilled water. The solution was then poured in a clean 
100mL beaker. The slide was immersed in the beaker so that half of the slide received the 
treatment and the other half remained untreated. This is followed by incubation for 15 minutes 
at room temperature. After the incubation, the slide was taken out of the beaker and washed 
with ddH2O to remove the amylase solution. The slide was left on the bench to air dry. 
PAS staining, image acquisition and analysis 
Staining the Slides 
The slides were stained with PAS kit according to the manufacturer’s instructions (SIGMA). 
The slides were first immersed in Periodic Acid Solution for 5 minutes followed by a wash with 
distilled water. The slides were then immersed in Schiff’s reagent for 15 minutes. This step was 
followed by 5 minutes of washing the slides with distilled water. Once the slides were dried, a 
coverslip was placed on the slides with the help of mounting media. Slides were examined 




Fig. 2) Step by Step Methodology of PAS Staining on PBMCs 
 
Figure. 2) Step by step methodology of PAS staining on PBMCs. A) Isolation of PBMC is achieved through 
ficoll gradient, the left panel shows the preparation before centrifugation, the right panel shows it after 
centrifugation where the buffy coat containing the PBMCs is observed in the center of the tube.  B) 
Isolated PBMCs are fixed onto the slide using formalin-ethanol fixative solution. The slide is gently rinsed 
with distilled water from a plastic wash bottle. C) The slide is then placed in a 100mL beaker half way 
filled with amylase solution, which will dissolve glycogen. The slide is gently rinsed. D) The slide is 
treated with periodic acid solution, where oxidation of saccharides takes place. Slides are gently rinsed; 
this will remove the excess periodic acid and stop the oxidation step. E) When the Schiff reagent is 
added to the slides, it will react with aldehydes created during the oxidation step. This colorless reagent 
will then result in a deep red magenta product. Slides are gently rinsed to remove the excess Schiff 
reagent (Tabatabaei Shafiei et al., 2014). 
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ImageJ Software 
To quantify the PAS positivity of the cells ImageJ, an open access public software published 
by NIH, was used (Schneider, Rasband, & Eliceiri, 2012). At least 50 cells from each slide was 
chosen at random and the intensity of the coloration of cells were measured. To remove the 
background signal, a value of the intensity of the background coloration was obtained. The 
value of each data point was subtracted from the background signal obtained from the area 
adjacent to each cell.  
Glycogen Assay  
This is an enzymatic detection kit (SIGMA) that measures the amount of glucose derived 
from glycogen in cells. The cells of interest first needed to be lysed to allow the internal glucose 
to release. A sample blank was also present to ensure the measured glucose was directly 
coming from glycogen.  
Cell Lysis 
The cells were transferred to a microcentrifuge tube and were centrifuged for 8 minutes at 
0.5 xg at 4oC. Carefully without disturbing the pellet, the supernatant was removed and saved 
in -20oC freezer for future analysis. The cells were washed with PBS to ensure the media is 
washed off. After the wash, the supernatant was completely removed. The cells were incubated 
in milli-Q water for 5 minutes then transferred to a heating block that was at 100oC. The tube 
was kept on the heating block for 5 minutes then centrifuged at 13000 xg for 5 minutes at room 
temperature. After this step, the insoluble matter was discarded and the supernatant, which 
was the lysate, was poured into a cryo vial. The lysates were kept in liquid nitrogen tank. On the 
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day of the analysis, the cryo tubes were taken out of the liquid nitrogen and thawed in 37OC 
waterbath.  
Assay 
The glycogen assay was done according to manufacturer’s instructions (SIGMA). For each 
sample, a sample blank was made which did not receive the hydrolysis Enzyme Mix treatment. 
This was done in duplicates. The values of glycogen assay are reported as fold change in 
glycogen concentration. The control groups (Nil) of every time point were corrected to report a 
value of 1.00. The glycogen concentrations of the activated groups are in respect to the control 
groups.  
Enzyme Linked Immunosorbent Assay (ELISA)  
This technique was used to measure the cytokine released from PBMCs upon activation. 
The supernatants containing the cytokines of interest were analyzed by ELISA. This is a 
colorimetric assay that quantifies the exact amount of cytokine released in the media. The steps 
were done according to manufacturer’s instructions (BD Bioscience, eBioscience). The wells of a 
96 well flat bottom plate were coated with the capture antibody and left overnight. The next 
day the plate was first washed once with wash buffer then the remaining protein-binding sites 
in the coated well were blocked with assay dilutent. The plate was left at room temperature for 
1 hour. Next the plate was washed three times before the diluted samples and the standards 
were added. The plate was incubated for 2 hours. Samples were removed and the plate was 
washed five times. Working detector, which is made of the combination of the detection 
antibody and secondary antibody conjugated with HRP (Horseradish Peroxidase), was added 
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and the plate was incubated for an hour at room temperature. The plate is then washed seven 
times. The detection substrate, TMB (3,3’,5,5’-tetramethylbenzidine) solution was  added to 
each well followed by an incubation of 15-30 minutes. An equal volume of stopping solution 
was added and the plate was read at wavelength of 450nm and at 570nm for correction.  
Flow Cytometry 
Cellular analysis was done using flow cytometry. Cells were stained with fluorescent 
antibodies against CD3, and a monocyte marker, CD14, then acquired on the flow cytometer 
(BD Accuri). Anti-CD3 and Anti-CD14 surface antibodies were mixed with the staining buffer and 
then added to the samples. The samples were put on ice for 30 minutes away from light. The 
samples were centrifuged at 13000 xg for 30 seconds to remove the supernatants. The cells 
were suspended in the staining buffer and analyzed by the flow cytometer. The flow cytometer 
excites cells individually with two lasers, and measures the fluorescence emission from the 
fluorochrome of any antibodies that attach to the marker of interest. Data analysis was done 
with FlowJo, a software for analyzing flow cytometry data, this package produces histograms 
and determines the percentage of positive cells expressing the marker.  
Results 
PAS Staining on Mouse Muscle Sections 
Muscle sections from mouse were first used as a positive control, and to establish the 
protocol. PAS positive particles were visible inside of muscle cells (Fig. 3A). As a negative control, 
slides were treated with amylase, which dissolves glycogen. Reduced PAS positive cells were 
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observed when the muscle sections were pre-treated with amylase (Fig. 3B). The staining 
around the cell membrane remained after amylase treatment. From the stained muscle cells, 
the number of PAS positive cells was counted. A total of 15 images per treatment (each image 
had approximately 7 cells) were counted. The percentage of PAS positive cells was calculated 
for each treatment (Fig. 4). The results showed that the percentage of PAS positive cells in 
muscle sections was 37%. Amylase treatment reduced the PAS-signal to 4% (p<0.001, Student's 













Fig. 3) PAS Staining of Mouse Muscle Sections 
 
Figure. 3) PAS Stained Mouse Muscle Sections. Mouse soleus muscle sections were stained with PAS and 
analyzed with light microscopy. Some samples were pre-treated with amylase. A) PAS-positive particles 
were visible inside of muscle cells. B) Less PAS positive cells were observed when the muscle sections 
were pre-treated with amylase. The staining around the cell membrane remained after amylase 










Fig. 4) Quantification of PAS positive Muscle Cells 
 
Figure. 4) Quantification of PAS positive Muscle Cells. The proportion of muscle cells that were PAS 
positive was counted from a representative slide without or with the amylase pre-treatment. As 
expected, 37% of muscle cells were positive for glycogen. Amylase treatment significantly reduced the 







Glycogen Analysis of Human Immune Cells 
PAS staining was attempted on whole human blood, which contains lymphocytes, red blood 
cells (RBCs), platelets and neutrophils. Blood films were made and stained with PAS. Differential 
interference contrast images confirmed the presence of mostly RBCs by revealing the 
characteristic disk-like shape of these cells. RBCs represented almost 99% of the entire field of 













Fig. 5) PAS Staining on Human PBMCs 
 
Figure. 5) PAS Staining on Human PBMCs. A) PAS-staining on PBMCs was performed. Two types of cells 
were observed. A.1-6) smaller cells (at 5μm) in non-amylase treated slides showed magenta particles 
consistent with glycogen. These cells could be resting cells. Larger cells (more than 5μm) in non-amylase 
treated cells had diffuse PAS-positive staining. These cells could be activated lymphocytes. B) PBMCs 
were treated with amylase for 15 minutes prior to staining, which diminished the PAS signal.  
Representative of seven different healthy human subjects. C) The PAS and hematoxylin staining done on 
whole blood slide. The arrow shows a PBMC surrounded by many red blood cell.  (Scale bar= 10µm)  
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Next, PBMC were prepared from whole blood, which eliminates RBCs, platelets and 
neutrophils. PBMC fractions are majority T cells, with monocytes, natural killer cells, and B cells 
making up the remainder. The PAS staining was performed on both amylase treated cells and 
non-amylase treated cells. Different sizes and shapes of PBMCs were visualized on the slides, 
and varying patterns of PAS positivity was seen among cells of different sizes (Fig. 5A.1-A.6). 
Cells that did not receive the amylase treatment appeared to have more PAS positive particles 
compared to amylase-treated slides (Fig. 5A and 5B).  
PAS positivity was calculated in both amylase treated and non-amylase treated slides. The 
cells observed on the slides were divided into 2 groups; larger cells (>5μm) and smaller cells (<5 
μm). This size was chosen because 5µM is the approximate size of a lymphocyte. The 
proportion of PBMCs that were PAS positive was counted from a representative slide with or 
without the amylase pre-treatment. 98% of the small-sized cells were positive for PAS. 40% of 
the larger cells were positive for PAS. Amylase treatment eliminated the PAS signal in the small 
cells (p<0.001, Student's t-test) and significantly diminished the PAS signal in the larger cells to 







Fig. 6) Quantification of PAS positive PBMCs 
 
Figure. 6) Quantification of PAS positive PBMCs. The proportion of PBMCs that were PAS positive was 
counted from a representative slide without or with the amylase pre-treatment. 98% of the small-sized 
cells were positive for PAS. 40% of the larger cells were positive for PAS. Amylase treatment eliminated 
the PAS signal in the small cells (p<0.001, Student's t-test) and significantly diminished the PAS-signal in 







Lysate samples were collected and the glycogen was measured using glycogen assay, which 
provides a quantitative measure of glycogen concentration. The sample contained a 
concentration of 0.6µg of glycogen in samples that were diluted 1:1, which means that 1 million 
cells contained 1.2µg of glycogen (Fig. 7). To confirm that the amount of glycogen measured 
was directly proportional to the amount of lysate present in the sample, the lysate was further 
diluted, which produced a corresponding reduction in glycogen (Fig. 7). These results confirm 













Fig. 7) Measurement of Glycogen Using Glycogen Enzymatic Detection 
 
  
Figure. 7) Measurement of Glycogen Using Glycogen Enzymatic Detection. Glycogen was measured 
according to manufacturer’s instructions. In brief, the protocol entails hypotonic lysis of 1x106 PBMCs 
followed by pelleting of insoluble material that contains glycogen. The pellet was washed and digested 
with hydrolysis enzymes yielding glucose, which was measured by spectrophotometry and compared to 
a standard curve. The cell lysate was diluted at the indicated ratios with hydrolysis buffer. Data is 
representative of three experiments. Significant levels of glycogen were detected in the 1:1 dilution 
(p=0.02, Student's t-test), and this signal titrated out as the lysate was further diluted (Tabatabaei 
Shafiei et al., 2014). 
 
 26 
Glycogen Measurements upon PMA Activation  
PBMCs were activated with PMA, a chemical that activates most immune cells. To ensure 
the activation treatment was working, the culture plate was examined under the microscope 
for signs of activation at each time point. The appearance of clumped cells indicated that PMA 
activated the samples (Fig. 8A). The pH of the media was lower when cells were activated, 
confirming that activation had occurred (Fig. 8B). The colour of the media was also more yellow, 
due to the presence of pH indicator in the cell culture media, which is consistent with the pH 
values (Fig. 8C). Both pH measurements and microscope observations of the cultures 











Fig. 8) Evidence of Activation of PBMCs with PMA 
 
Figure. 8) Evidence of Activation of Immune Cells with PMA. A) The cells in the culture plate were 
analyzed under a light microscope (20X objective) at day one, day two and day three. Activated Immune 
cells aggregate into clumps at the bottom of the culture plate. B) pH was measured in each sample. The 
cells that had the activation treatment for longer times had a more acidic media than the nil non-
activated (resting) condition. C) The pH indicator, phenol red, of the media provides an indication of the 
acidity of each group, where yellow means more acidic. Top Row from left to right: 1) no activation, 2) 
30 minutes post activation, 3) 1 day post activation. Bottom Row from left to right: 4) 2 days post 
activation, 5) 3 days post activation and 6) PBS, no cells. 
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Glycogen measurements, PAS staining and glycogen assay, were done at time points of 30 
minutes, 1 day, 2 days and 3 days post PMA activation treatment. Microscopy analysis of PAS 
stained cells revealed the gradual increase in glycogen in activated cells (Fig. 9A). The intensity 
of the PAS positivity of the cells was measured and recorded for each time point. There was an 
increase in glycogen concentrations of the PMA activated cells of 30 minutes, day 1 and day 3 
groups, as compared to the resting cells (p<0.05)(Fig. 9B). On Day 2 there was a trend towards 
higher glycogen that did not reach significance. Using the glycogen assay, the glycogen 
concentrations were significantly higher in each time point as compared to resting cells 
(p<0.05). These findings from glycogen assay are consistent with the results of PAS staining and 
demonstrate that there is an increase in glycogen concentrations of the activated cells as 










Fig. 9) Glycogen Content of PBMCs upon PMA Activation 
 
Figure. 9) Glycogen Content of PBMCs upon PMA Activation. A) PAS staining was done on PBMCs. The 
experiment was done in time points of 30 minutes, Day 1, Day 2 and Day 3. The images on the left 
column are the cells that received the PMA activation treatment and the images on the right column are 
the cells that are in resting state (Nil). (Scale bar= 10μm). B) The intensity of the coloration of the cells 
was analyzed with Image J software. Significant increase of coloration intensity was observed in 30 min, 
day, 2, and day 3 activated groups compared to non-activated cells (AU= Arbitrary Units). The data is 
pooled from 3 individual experiments. C) The glycogen content of PMA activated and non-activated (nil) 
PBMCs was measured with glycogen assay. There was a significant increase in the fold change of 
glycogen accumulation upon PMA activation. Pooled from 3 individual experiments. (*p<0.05, One-way 
ANOVA followed by Fisher LSD). 
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Glycogen Measurements upon T Cell-Specific Activation 
To determine the contribution of T cells, PBMCs were activated with T cell-specific activator 
that provides the two necessary signals for proper T cell activation (CD3 and CD28, which are 
only found on T cells). Glycogen measurements was done through PAS staining and glycogen 
assay at time points of 30 minutes, 1 day, 2 days and 3 days post activation treatment. To 
ensure the activation was effective, supernatants of the cultures were collected at each time 
point and they were measured for various interleukins (ILs). ELISA was used to measure the 
amounts of IL-1B and IL-6, to determine if the monocytes were activated, alongside IL-17 and 
IL-2 to determine if the T cells were activated (Figure 10.A-D). The level of T cell-specific 
cytokines, IL-2 and IL-17 increased. The monocyte cytokines increased as well, which indicates 
that they were activated as a by-product of the T cell-specific activation. Glycogen 









Fig. 10) Evidence of Activation of PBMCs with T Cell-Specific Activation (IL-1β, IL-6, IL-17, IL-2) 
 
Figure. 10) Evidence of Activation of PBMCs with T Cell-Specific Activation (IL-1β, IL-6, IL-17- IL-2). A): 
ELISA results done on the supernatants of activated (Act) and non-activated (Nil) groups. The ILs 
secretion was used as a validation of activation. A) IL-1β was tested to determine monocyte activation. 
IL-1β β started to increase from 30 minutes post activation treatment and remained high through day 3. 
The concentration of IL-1β reached a plateau by day 3. B) IL-6 concentration was measured as a second 
activation marker for monocytes. There is an increase in secretion of IL-6 starting from 30 minutes post 
activation treatment and reaching a plateau by day 3. C) IL-17, a T cell activation marker, was used to 
validate the activation of T cells in the cultures. D) IL-2 was measured as a second activation marker for T 





The cells exhibited the gradual increase of PAS positivity of the cells upon treatment with T 
cell-specific activation (Fig. 11.A). The intensity of PAS positivity of the cells was measured at 
each time point (Fig. 11.B). Results show activated groups of 30 minutes, day 2 and day 3 had a 
greater PAS positivity compared to their respective non-activated groups (p<0.05, One-way 
ANOVA). When glycogen levels were measured with glycogen assay, a higher concentration of 
glycogen was found in activated cells as compared to the non-activated groups (p<0.05, One-
way ANOVA) (Fig 11.C). The results from glycogen assay are consistent with the results of PAS 












Fig. 11) Glycogen Content of PBMCs Upon T Cell-Specific Activation  
 
Figure. 11) Glycogen Content of PBMCs Upon T Cell-Specific Activation. A) PAS staining was done on 
activated (Act) and resting PBMCs (Nil). The experiment was done in time points of 30 minutes, Day 1, 
Day 2 and Day 3. The images on the left column are the cell that received the activation mix and the 
images on the right column are the cells that are in resting state. (Scale bar= 10μm). B) The intensity of 
the coloration of the cells was analyzed with Image J software. Significant increase of coloration 
intensity was observed in 30min, day 2 and day 3 activated groups compared to non-activated groups. 
Data pooled from 3 individual experiments (AU= Arbitrary Units). C) The glycogen content of T cell-
specific activated and non-activated PBMCs was measured with glycogen assay. There was a significant 
increase in the fold change of glycogen accumulation upon PMA activation. Pooled from 3 individual 
experiments. (*p<0.05, One-way ANOVA followed by Fisher LSD). 
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Manipulation of Nutrient Availably through Serum Titration 
The major source of glucose in these cultures is derived from the fetal bovine serum (FBS) 
supplement. To manipulate the nutrient availability, PBMCs were activated and cultured in 
media containing 5% FBS for 1 day, followed by a gradual change in the level of FBS in the 
media over the course of 3 days (Fig 12.A). The initial amount of glycogen at 5% serum was 8 
ng/mL. After 3 days with 1% serum, the amount of glycogen was reduced to 3ng/mL (p<0.05, 
One-way ANOVA). There were higher levels of glycogen in the other serum values (2%, 5%, 8%, 
and 11%) as compared to 1% serum. This demonstrates that glycogen concentration was 











Fig. 12) Manipulation of Nutrient Availably through Serum Titration 
 
 
Figure. 12) Manipulation of Nutrient Availably through Serum Titration. Glycogen Content of PBMCs that 
were cultured in different nutrient levels and measured with glycogen assay. Prior to changing the 
media, all groups were cultured and treated with T cell-specific activation in 5% media for 24 hours 
(Control). Following that, the cells had their media changed gradually over 3 days to reach the final FBS 
concentrations of 1%, 2%, 5%, 8% and 11%. The media that was changed included fresh activation to 
hold the activation stimulus constant. On day 3, the cells were lysed and glycogen analysis was done 






One caveat of this experiment is that manipulating nutrient levels could result in more dead 
cells, or a change in the proportion of lymphocyte subtypes. To address this issue, flow 
cytometry was used to obtain an estimate for the amount of live cells, and the proportion of T 
cells and monocytes in the samples. In all serum levels tested (1%, 2%, 5%, 8%, and 11%), the 
proportion of T cells was ~70%, with less than 5% being monocytes, and the proportion of live 













Fig. 13) Cellular Composition Of PBMC Used for Glycogen Analysis in Serum Titration 
Experiment 
 
Figure. 13) Cellular Composition of PBMC Used for Glycogen Analysis in Serum Titration Experiment. 
Before glycogen analysis, the cellular composition of the samples was determined by flow cytometry 
using fluorescent antibodies to detect a T cell-specific marker (CD3) and a monocyte-specific marker 
(CD14). A) The laser scattering properties of the cells is plotted in a representative sample (11% serum). 
Each dot is an event, the heat map indicates multiple cells in the same spot. Based on this pattern, the 
cells that are alive were gated (live gate). B) The fluorescent emission was plotted from the cells of the 
live gate. In quadrant 1 (Q1) the T cells are found, in Q2 (and Q3) the monocytes are found, and any 
other type of lymphocyte falls into Q4. C) The different percentage FBS in serum conditions are 




The purpose of my Master's thesis was to demonstrate the presence of glycogen in 
lymphocytes and investigate how glycogen content is affected upon activation. The role of 
nutrient availability on glycogen concentration was also addressed.  
Techniques Used 
To measure glycogen, two main techniques were used; periodic acid Schiff’s (PAS) staining 
and enzymatic detection kit (glycogen assay). This work is the first to use both techniques on T 
cells. These techniques are complimentary to each other because PAS staining provides 
information on the intensity of glycogen positivity of intact cells, while the glycogen assay 
provides information about glycogen concentrations of the whole sample.  
To analyze PAS stained images, ImageJ software was used to measure the overall intensity 
of the purple coloration in each cell. This approach differs from the literature which used a 
scoring system based on the number of granules in the cells, where a certain number of 
granules was used as a cut-off point for positivity (Mitus et al. 1958; Gärtner and Nordén 2009). 
Scoring granules in this fashion introduces a bias because glycogen patterns can be subjective, 
which is avoided by measure the overall intensity of the purple coloration. The scaling systems 
present in literature are inconsistent and there is no universal scaling system that would 




PAS Staining on Mouse Muscle Sections 
PAS staining was first done on mouse soleus muscle sections as a positive control. The 
human soleus muscle consists of 60% slow twitch and 40% fast twitch muscle fibres. This means 
40% of the muscle fibres have more glycogen storage compared to the other 60%. A mouse 
(Mus spretus) soleus muscle has similar percentage compositions; 64% slow twitch fibres and 
36% fast twitch (Drummond, 1967; Totsuka et al., 2003). The analysis revealed 37% PAS positive 
muscle cells, which is similar to the percentage composition of fast twitch fibres in the muscle 
used (Fig 4). There was a clear staining visible on the cell membrane; this was because PAS also 
stains elements such as glycoproteins, glycolipids and mucins that are found on the cell 
membrane. However, Amylase used as a negative control in the slides can only dissolves 
glycogen. This supports the fact that the dark particles in the non-amylase treated cells are in 
fact glycogen particles.   
Glycogen Analysis of Human Immune Cells 
Healthy human subjects were recruited based on the following selection criteria: anyone 
above the age of 18 who was comfortable with blood draws and needles, not taking any 
prescriptions medications that affect blood pressure or immune function, not suffering from 
chronic medical conditions (autoimmune disease, cancer, lung or heart disease) and did not 
receive any vaccinations within the past 2 months prior to participation.    
The initial experiment was done using human whole (un-fractioned) blood. PAS staining on 
whole blood films was not efficient, because of the presence of mostly RBCs that weren’t of 
interest for this study. Therefore, it was decided to isolate the cells of interest (PBMCs) from 
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the whole blood samples and stain them separately, since this technique eliminates RBC 
(Fig.5C). 
Amylase was chosen as a negative control treatment.  Even when amylase treatment was 
used, there was a dark rim stained at the outline of cells, similar to what was seen with the 
muscle cells.   This was likely due the fact that PAS also stains other molecules of the cell 
membrane. Unlike glycogen polymers, these molecules are not digested by amylase treatment, 
resulting in them picking up the stain particles of PAS staining (Fig. 5A and 5B). These results 
indicate that PBMCs contain glycogen positive particles and diffuse glycogen throughout the 
inside of the cell that are dissolved once the cells are treated with amylase. PBMCs show 
different patterns of glycogen positivity, suggesting the varying amounts of glycogen in these 
cells. Some of the patterns shown in Fig. 5A where the cells show diffused or granular patterns 
covering the entire cell, diffused pattern on one side and granular pattern on the other side of 
the cell, a mixture of both patterns or no pattern of glycogen positivity.  Conventional antibody 
staining yields a brown or purple colour, which is difficult to discriminate from the PAS staining.  
The cells observed on the slides were analyzed based on their size; larger cells (>5μm) and 
smaller cells (<5 μm). The reason for this classification is that PBMC population is mostly made 
up of lymphocytes including, T cells, natural killer cells, B cells, and myeloid cells including 
monocytes (myeloid) and a very small proportion of dendritic cells. The cells that are larger 
than 5μm are anticipated as monocytes and some dendritic cells, and cells that are the same 
size or smaller than 5μm are expected to be resting lymphocytes (Downey et al., 1990; Goya et 
al., 2008; Marguerat & Bähler, 2012). Nearly all of the small cells were positive for glycogen, 
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while only a proportion of the larger cells were positive, suggesting that lymphocytes express 
more glycogen than myeloid cells. Glycogen levels in cell lysates were analyzed by glycogen 
assay. The amount detected was 1.2µg per 106 lymphocytes. This value was comparable to the 
report from Hedeskov et al, who found that 1010 lymphocytes from healthy humans contained 
31 mg of glycogen, which is equivalent to 3.1µg per 106 lymphocytes (Hedeskov & Esmann, 
1967). The glycogen in lymphocytes represents between 2-4% of the glucose that is used by 
human lymphocytes, the rest of the glucose is used for glycolysis, aerobic respiration (Krebs 
cycle), and pentose phosphate pathway (Hedeskov 1968; Quaglino & Hayhoe 1965; Hedeskov 
and Esmann 1967). To put that value in perspective, glycogen content in neutrophils is 13.6 µg 
per 106  cells (Gahrton & Yataganas, 1976). 
Glycogen Measurements upon PMA Activation  
All activation experiments were analyzed at 30 minutes, day 1, day 2 and day 3 to allow 
enough time for PBMCs to become fully activated (Ling and Holt 1967). It also provided the 
advantage of observing the gradual change in glycogen concentrations of the cells. PMA was 
initially used to activate because it stimulates most cells and was thus a positive control. PMA-
activated Immune cells were observed to cluster at the bottom of the culture plate, while 
resting cells were evenly distributed on the plate (Pulvertaft & Pulvertaft, 1967). This pattern is 
expected for PMA activated cells (Fig. 8A). The activation was also measured by the change in 
the pH of the media; the pH was lower in activated samples. This occurs due to lactic acid as a 
by-product of glycolysis.  
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Glycogen is higher at 30 minutes post PMA treatment as compared to resting cells, a 
pattern that remains through 3 days post PMA activation. This data demonstrates the direct 
association of glycogen build-up and PMA activation, suggesting that PMA induces the glycogen 
synthesis pathway  
Glycogen Measurements upon T Cell-Specific Activation 
Using a non-specific activator as positive control revealed that lymphocytes accumulate 
glycogen, however, it is not clear which cells are responding. Upon activation of PBMCs with T 
cell- specific activators, there was a similar increase in glycogen concentrations.  This suggests 
that due to activation, immune cells increase the glycogen production, possibly because of the 
increase in glucose uptake in activated PBMCs. 
The findings from glycogen assay and PAS staining are consistent. At each time point there 
is an increase in glycogen concentrations of the activated cells as compared to the resting cells. 
The results of both activation treatments (PMA and T cell-specific activation) are consistent 
thus validating the effect of activation on the increase of glycogen concentration. The 
production of glycogen is enzymatic. The rapid rise in glycogen confirms that the enzymes are 
already present and that there is likely no gene expression required. With PMA activation, this 
rapid rise was delayed and that could be due to the fact that PMA is a general activator and 
activation is accelerated when it is obtained through T cell- activators.  
 To confirm that T cells were being activated, cytokines were measured. As expected T cell-
specific cytokines were found including IL-1, an early cytokine, and IL-17, a cytokine that peaks 
later than IL-2. Other cytokines that are derived from monocytes, IL-1, IL-6, showed that 
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monocytes were also activated.  Despite the presence of activated monocytes, there were very 
few monocytes detected in the samples used for glycogen assay. This is likely because activated 
monocytes stick very strongly to plastic surfaces, but to analyze glycogen, only the floating cells 
are taken.  
Previous studies tested the activation effects of lymphocytes on glucose metabolism, using 
phytohaemagglutinin (PHA) as an activator of T cells. PHA is a lectin-derived chemical extracted 
from legumes especially kidney beans. PHA acts as a mitogen on lymphocyte cells, which causes 
them to clump and proliferate much like they do in their activated state. Glycogen was found to 
accumulate in the PHA-activated activated lymphocytes (Hamelryck et al., 1996; Hedeskov, 
1968; Helderman, 1981). This is consistent with the findings of the current study where more 
direct activation treatments (PMA and T cell-specific activators) were used. One limitation of 
the previous studies was that they only used one technique to measure glycogen, while in this 
study two techniques were used to measure glycogen.  
Arrizabalaga et al. investigated the glycogen content by measuring glycogen concentration 
in a human T cell line (Arrizabalaga, Lacerda, Zubiaga, & Zugaza, 2012). The authors found that 
glycogen decreased when the cell line was activated. In contrast, in the current study glycogen 
accumulated in activated lymphocytes. One key difference between Arrizabalag and the current 
study is that primary lymphocytes from healthy donors are more physiologically relevant than a 
T cell line, which has chromosomal abnormalities. 
  
 44 
Manipulation of Nutrient Availably through Serum Titration 
The change in the serum concentration in the media of the culture had to be gradual so as 
to allow the cells to adapt to the new environment and prevent shocking the cells. In low serum 
levels there was less glycogen. The possible explanation for the higher glycogen concentration 
in the cells that were cultured in high nutrient levels (8% and 11% FBS) was that they had more 
glucose available. However, all groups were first cultured in 5% FBS and thus they all had the 
same amount of initial glycogen concentrations prior to suspension in medias with different 
nutrient availabilities. With lower nutrient levels (1% and 2% FBS), the cells expressed lower 
amounts of glycogen concentrations suggesting glycogen may have been used a fuel source by 
the cells. The proportion of live cells on average was 74% with a range of only 5%, ruling out the 
possibility that cells died more in the low serum levels. The proportion of T cells was 
approximately the same in all serum conditions (~70%) and very few monocytes were present 
(less than 5%). Once PBMCs are incubated in culture plates, most of the monocytes present in 
this mixed population will stick to the bottom of the well and will not detach unless 
trypsinization techniques are used. This was to our advantage since the cells that were in 
suspension would end up being enriched in T cells and low levels of monocytes are present.  
Formation of glycogen upon activation could be beneficial for activated T cells in many ways. 
With the increased glucose uptake upon activation, the concentration of glucose inside the 
cytoplasm of T cells is higher than the outside environment. This is harmful due to the fact that 
the difference in the osmotic pressure could cause the cells to burst. On the other hand, if all of 
the glucose inside the cytoplasm is processed at once, it will cause the activated T cells to go 
towards a state called hyperactivity (Maciver et al., 2008). At this state healthy T cells will start 
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to promote programmed cells death, which is called apoptosis. Cancer cells are resistance to 
apoptosis and thus due to hyperactivity they become pathogenic (Maciver et al., 2008; Nicot, 
2015). Formation of glycogen reduces the amount of soluble glucose thus it may prevent 
hyperactivity and osmotic imbalances.  
Future Directions 
I speculate that the blood glucose levels would correlate to the amount of glycogen in the 
lymphocytes. A future direction of this project is to measure blood glucose levels from 
participants prior to the blood draw.  An interventional study could also look at the effects of 
controlled diets and how eating different amounts of glucose would alter the lymphocyte 
glycogen levels. Another direction is to inhibit key enzymes in glycogen metabolism such as 
glycogen phosphorylase, or glycogen synthase, and investigate how that will affect activation 
and cell survival and cytokine production. In this way, one could test if glycogen is required for 
immune cell activation; if a glycogen phosphorylase inhibitor prevented immune cell activation 
that would be a way to demonstrate the function of glycogen.  
Conclusion  
This project demonstrates the presence of glycogen in resting immune cells from healthy 
people through two independent techniques (PAS staining and glycogen assay). The effect of 
activation on glycogen content of immune cells was examined through the use of two different 
immune cell activators (PMA and anti-CD3/anti-CD28 mixture). Upon activation of immune cells, 
there is a significant increase in glycogen accumulation. Finally, the role of nutrient availability 
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was studied for this project. The findings suggest that activated immune cells may utilize 
glycogen in times of low nutrient availability. 
 This thesis is relevant in the context of T-cell acute lymphoblastic leukemia (T-ALL). T-ALL 
patients have less glycogen positivity than other types of cancer  (Lilleyman et al, Andreewa et 
al., and Huhn et al.; supplemental table 1). The cancer cell could interrupt the normal 
regulation of the glycogen pathway in order to obtain energy to grow aberrantly, while in 
healthy people T cells store glycogen until it is needed. In T-ALL the PI3K/Akt pathway, which is 
initiated by CD28 co-stimulatory signal in healthy cells, is always on. One of the functions of this 
pathway is to regulate the increase in glucose uptake of the cells. This implies that in this 
disease there is abundance of glucose available to the cancer cell. Since reduced levels of 
glycogen are expressed in these cells, it is indicated that the glucose inside these leukemic cells 
is being processed to create energy, which may have caused their hyperactivity (Barata et al., 
2004; Durinck et al., 2015; Nicot, 2015). Glycogen stores could prevent harmful outcomes that 
follow high levels of glucose and ATP inside the cytoplasm. The more we understand the 
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Supplementary Table 1: Comparison of three papers from the literature that measured PAS 
Positivity of Lymphocytes in Patients Suffering from T-ALL 
 
Supplementary Table 1: PAS positivity of lymphocytes was measured in patients suffering from T-ALL 
and non-T-ALL. Each study had a different scaling system however the conclusion of the analysis was 
consistent between all studies. A reduction in glycogen positivity of lymphocytes was observed in 
patients suffering from T-ALL as compared to non-T-ALL patients. Data adapted from Lilleyman et al., 
Andreewa et al., and Huhn et al.    
 
